Abstract

ObjectivesTo evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison.MethodsBetween 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR).ResultsRelative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001).ConclusionsOur findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.

Highlights

  • Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide

  • Our findings suggest that patients with advanced tumour stages of colorectal cancer (CRC) and especially rectal cancer benefit most from a multidisciplinary and guidelinesoriented treatment at Certified Oncology Centres

  • P-Values (Raw) accredited by the German Cancer Society (DKG), with national survival rates published by the Munich Cancer Registry (MCR) and international survival rates obtained from the American SEER-database [12, 13]

Read more

Summary

Introduction

Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide. Between one and two million cases are diagnosed every year [1]. It is one of the leading causes for cancerrelated deaths worldwide alongside lung cancer and breast cancer [2, 3]. In Germany, the 5-year-prevalence for CRC (ICD-10, C18-21) was 116,000 among men and 98,000 among women in 2013 [4]. There was an increase of 38% in the 5-year-prevalence rate for women and 79% in men between 1990 and 2004 in Germany [4].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call